Galmed Pharmaceuticals (NASDAQ:GLMD) has been given a $14.00 price objective by equities researchers at Maxim Group in a note issued to investors on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective indicates a potential upside of 38.89% from the company’s current price.

GLMD has been the subject of a number of other reports. Roth Capital began coverage on Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $32.00 price target for the company. ValuEngine lowered Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Seaport Global Securities reissued a “buy” rating and set a $19.00 price target on shares of Galmed Pharmaceuticals in a research note on Friday, October 6th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Galmed Pharmaceuticals in a research note on Friday, October 27th. Finally, Zacks Investment Research lowered Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $18.30.

Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) traded up $0.69 during mid-day trading on Wednesday, hitting $10.08. The company had a trading volume of 104,406 shares, compared to its average volume of 91,250. Galmed Pharmaceuticals has a 52-week low of $3.54 and a 52-week high of $10.70. The company has a market cap of $127.84, a price-to-earnings ratio of -8.26 and a beta of 2.46.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. bought a new stake in shares of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned approximately 0.15% of Galmed Pharmaceuticals as of its most recent SEC filing. 9.85% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/03/maxim-group-analysts-give-galmed-pharmaceuticals-glmd-a-14-00-price-target.html.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.